Tirzepatide (GIP/GLP-1 Agonists) for Diabetes: Pharmacology Made Easy episode artwork

EPISODE · Jan 26, 2026 · 31 MIN

Tirzepatide (GIP/GLP-1 Agonists) for Diabetes: Pharmacology Made Easy

from This Is Why with Dr. Busti · host Anthony Busti, MD, PharmD, MSc, FNLA, FAHA

Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity.  In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/precautions, and practical tips for patient counseling (nausea, GI effects, injection technique, and expectations).You’ll learn how to:- Tirzepatide overview: Mounjaro vs Zepbound- GIP/GLP-1 agonist mechanism (dual incretin)- Clinical use in type 2 diabetes- A1C lowering + weight loss effects- Adverse effects, warnings, and counseling pearlsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tirzepatide-mounjaro-zepbound-gip-glp1-agonist-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#tirzepatide #mounjaro #gipglp1 #type2diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Episode metadata supplied by the publisher feed · Published Jan 26, 2026

Embed this episode

Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity. In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Tirzepatide (GIP/GLP-1 Agonists) for Diabetes: Pharmacology Made Easy

0:00 31:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of This Is Why with Dr. Busti?

This episode is 31 minutes long.

When was this This Is Why with Dr. Busti episode published?

This episode was published on January 26, 2026.

Can I download this This Is Why with Dr. Busti episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!